

BRAWN BIOTECH LIMITED
(formerly known as Brawn Pharmaceuticals Limited)

CIN: L74899DL1985PLC022468

REGD. OFFICE: C-64, LAJPAT NAGAR-I, NEW DELHI-110024

Statement of Standalone Audited Financial Results for the quarter & year ended 31st March, 2016

PART I						(Rs. in Lakhs)
	Particulars	3 months ended 31/03/2016	Preceding 3 months ended 31/12/2015	Corresponding 3 months ended 31/03/2015 in the previous year	Year to date figures for current period ended 31/03/2016	Previous Year ended 31/03/2015
		Audited	Unaudited	Audited	Audited	Audited
1	Income from operations					
	Net sales/ income from operations (Net of excise duty)	1,138.18	1,247.20	776.51	4,562.24	3,798.08
	Other operating Income	18.19	24.08	18.30	126.14	66.56
	Total income from operations (net)	1,156.37	1,271.28	794.81	4,688.38	3,864.64
2	Expenses					
	(a) Cost of materials consumed	-	-	-	-	-
	(b) Purchases of stock-in-trade	959.27	1,087.69	686.78	3,998.86	3,332.58
	(c) Changes in inventories of finished goods, work-in- progress and stock-in- trade	16.61	29.14	1.15	53.24	68.31
	(d) Employee benefits expense	59.31	51.36	44.43	186.18	151.82
	(e) Depreciation and amortisation expenses	0.56	0.94	0.25	3.32	2.62
	(f) Other expenses	111.59	71.78	39.30	307.52	256.20
	Total expenses	1,147.35	1,240.91	771.91	4,549.12	3,811.53
3	Profit / (Loss) from operation before other income,finance costs and exceptional items (1-2)	9.03	30.37	22.91	139.26	53.11
4	Other income	0.97	2.99	3.60	0.80	5.18
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3±4)	10.00	33.36	26.50	140.07	58.29
6	Finance Cost	0.45	1.69	9.63	9.57	10.45
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5±6)	9.55	31.67	16.88	130.50	47.84
8	Exceptional items	-	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7±8)	9.55	31.67	16.88	130.50	47.84
10	Tax expense	27.49	8.03	-	35.52	19.41
11	Net Profit / (Loss) from ordinary activities after tax (9 ± 10)	(17.95)	23.64	16.88	94.97	28.43
12	Extraordinary items (net of tax expense)	-	-	-	-	-
13	Net Profit / (Loss) for the period (11±12)	(17.95)	23.64	16.875	94.97	28.43
14	Paid-up equity share capital (Face Value of the Share shall be indicated)	300.03	300.03	300.03	300.03	300.03
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	252.57	306.63	193.71	252.57	193.71
16 i	Earnings per share (before extraordinary items) (not annualised): in Rs.					
	(a) Basic	(0.60)	0.79	0.56	3.17	0.95
	(b) Diluted	(0.60)	0.79	0.56	3.17	0.95
16 ii	Earnings per share (after extraordinary items) (not annualised): in Rs.					
	(a) Basic	(0.60)	0.79	0.56	3.17	0.95
	(b) Diluted	(0.60)	0.79	0.56	3.17	0.95

Notes:

- 1 The above results have been audited by the Statutory Auditors and reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 27th May, 2016.
- 2 The Board has recommended a final dividend of Rs. 1/- per equity share of face value of Rs. 10/- each for the year ended 31st March 2016 subject to approval of shareholders in the Annual General Meeting of the Company.
- 3 The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Accounting Standard-17 dealing with Segment Reporting.
- 4 The figures for the quarter ended 31st March 2016 and 31st March 2015 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the 3rd quarter of the relevant financial year.
- 5 Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
For Brawn Biotech Limited

Place: New Delhi
Date: 27.05.2016

Brij Raj Gupta
Managing Director